Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Over the past month, shares of this world's largest biotech drugmaker have returned +6.5%, compared to the Zacks S&P 500 composite's +0.5% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Amgen falls in, has gained 1.3%. The key question now is: What could be the stock's future direction?
Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Amgen is expected to post earnings of $5.21 per share for the current quarter, representing a year-over-year change of +4.8%. Over the last 30 days, the Zacks Consensus Estimate has changed -0%.
For the current fiscal year, the consensus earnings estimate of $20.82 points to a change of +4.9% from the prior year. Over the last 30 days, this estimate has changed +0.2%.
For the next fiscal year, the consensus earnings estimate of $21.29 indicates a change of +2.2% from what Amgen is expected to report a year ago. Over the past month, the estimate has changed +0.3%.
Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Amgen is rated Zacks Rank #3 (Hold).
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
Even though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.
In the case of Amgen, the consensus sales estimate of $8.86 billion for the current quarter points to a year-over-year change of +5.6%. The $35.22 billion and $35.78 billion estimates for the current and next fiscal years indicate changes of +5.4% and +1.6%, respectively.
Amgen reported revenues of $8.15 billion in the last reported quarter, representing a year-over-year change of +9.4%. EPS of $4.9 for the same period compares with $3.96 a year ago.
Compared to the Zacks Consensus Estimate of $7.95 billion, the reported revenues represent a surprise of +2.47%. The EPS surprise was +17.79%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Amgen is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Amgen. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amgen Inc. (AMGN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
23 minutes ago
- CNBC
5 stocks to buy for the second half from investors
The most popular stocks for investors heading into the second half of 2025 include Amazon , Nvidia and Newmont . The first half of the year was characterized by high volatility, as President Donald Trump's escalating trade war cast a shadow over the market. Although stocks have since recovered from the lows of the year in April, the Dow Jones Industrial Average remains underwater year to date. In the same time period, the S & P 500 has gained 1.5%, while the Nasdaq Composite has inched up 0.7%. But with trade negotiations ongoing, Wall Street is cautiously optimistic entering the second half of the year that deals can be reached. Earlier this month, the U.S. and China called a truce in the ongoing dispute. A smattering of sell-side shops have recently hiked their S & P 500 forecasts, including Deutsche Bank , RBC , Barclays , JPMorgan and Citigroup . CNBC Pro asked five investors for their top five stock picks heading into the second half of 2025. The most popular stock among these professionals was Nvidia, with three investors highlighting the chipmaker. Two investors also singled out Amazon and Newmont as potential winners. Jay Woods, chief global strategist at Freedom Capital Markets Investor Jay Woods selected three technology names within his top five stock picks: Nvidia, Amazon and Cisco . Shares of Nvidia have risen 5% year to date, but Woods said that there's still more room to go. "It got through the tariffs, and now price action is telling us that it wants to go higher. Once this stock breaks 150 and closes above there, I think it's poised to have a great second half run," he said. "Maybe not a historic run by Nvidia's standards, but a run of, say, 25% to 30% to get this stock towards 200 by year end." Woods added that Amazon looks set up both from a technical and fundamental standpoint to rally into year end, with Amazon Web Services poised to boost its revenue streams. Cisco, on the other hand, is a "long-forgotten stock" that could rise on both increasing cybersecurity and artificial intelligence demand. Woods singled out generator manufacturer Generac as a "beaten-down" stock for investors looking for long-term growth. The company looks increasingly attractive in the second half of 2025 due to the arrival of hurricane season, which is from June 1 through Nov. 30. Coinbase is another name that could have further to go, Woods said. "The stock is breaking out now technically. It has the administration behind it," he said. "The crypto space has now been legitimized and has legs to stand on." Jed Ellerbroek, portfolio manager at Argent Capital Management Echoing Woods, Jed Ellerbroek cited Nvidia as a potential second-half winner due to the upcoming release of its Blackwell Ultra chip, which is expected to meet with "exceptionally high demand." Likewise, the portfolio manager at Argent Capital Management highlighted Amazon for its strong cloud computing business, Amazon Web Services; more effective advertisements; and potential benefits from infusing AI tools into its e-commerce website. Aerospace manufacturer TransDigm Group is another pick. Ellebroek said the company has benefited from strong demand in all three of its major end markets: airplane production, replacement and maintenance, and defense. Meanwhile, ServiceNow looks attractive as it continues to acquire AI-centric companies and build AI functionality into its products, he said. Finally, Ellerbroek underscored life sciences and bioprocessing company Danaher as a favorite. "The bioprocessing end market is finally improving after two tough years," he said. "We've seen revenues go from contracting to growing, and we think that growth is going to accelerate as this year progresses." Jay Hatfield, founder and CEO at Infrastructure Capital Advisors Investor Jay Hatfield was the third to highlight Amazon as a second-half winner. While the company certainly has an AI tailwind, investors also seem to be underappreciating the extent of its potential cost cutting, according to Hatfield. The founder and CEO of InfraCap also brought up financial stocks Goldman Sachs and KKR , which he expects to rally on a stronger mergers and acquisitions market in the latter half of the year. Semiconductor manufacturer Broadcom is a "reasonably priced" stock that could continue riding the AI wave from here, he said. Hatfield anticipates shares will rise as orders from its clients, the major hyperscalers and cloud providers, ramp up. Hatfield's final pick was Cheniere Energy . He expects upcoming trade deals to create higher demand for U.S. natural gas. David Miller, co-founder and CIO at Catalyst Funds Instead of singling out Amazon like the aforementioned three investors, David Miller highlighted Meta as his preferred AI play. "While a lot of people are very concerned about where the spend is going and whether AI can really be monetized, Meta is one of those companies that's already doing it," the co-founder and CIO at Catalyst Funds told CNBC. "We think they have a great revenue engine. It's incredibly efficient." Ridesharing stock Uber could provide another good opportunity for investors, Miller said, due to its strong ad business, rising bookings growth and robust margin expansion and free cash flow. Meanwhile, brokerage stocks Raymond James and LPL Financial could offer discounts since both names are trading at a cheaper valuation than the overall index, but providing investors with materially stronger revenue growth and earnings, he said. Finally, Miller selected gold miner Newmont as a potential winner as the price of the precious metal continues to rally. Central bank gold buying has driven up its value as it's traditionally considered a safe-haven asset. Sam Stovall, chief investment strategist at CFRA Like Miller, CFRA chief investment strategist Sam Stovall also likes Newmont due to his bullish outlook on gold prices. Stovall said more investors have flocked to gold amid heightened global geopolitical risks. Rising tensions are also contributing to an increased need for military deterrence, Stovall said, pointing to aerospace and defense stock RTX as an attractive pick. He also singled out energy stock Baker Hughes for its robust balance sheet and strong prospects in the liquid natural gas market. The strategist said he likes Chipotle Mexican Grill for its undervalued growth prospects. He said he sees the company as more resilient than its peers and expects it has "more compelling opportunities to improve restaurant-level margins." His final top stock pick was streaming platform Netflix , which he said could receive a boost from ad-supported plans, growing advertising revenue potential and its expansion into gaming and live sports. "The company's ability to curate local content and personalize user experience globally sets it apart from competitors," he told CNBC. "Netflix's subscriber base is less sensitive to an economic downturn for household entertainment versus significantly higher ticket prices for live concerts and sporting events."
Yahoo
an hour ago
- Yahoo
How Is Hologic's Stock Performance Compared to Other Health Care Equipment Stocks?
With a market cap of $14.3 billion, Hologic, Inc. (HOLX) is a Massachusetts-based medical technology firm, primarily focused on women's health. The company develops, manufactures, and sells a comprehensive suite of solutions, including molecular diagnostics, medical imaging systems, and surgical devices Companies worth $10 billion or more are generally described as 'large-cap stocks,' and Hologic fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the medical instruments & supplies industry. The company benefits from robust innovation, supported by over 7,000 patents, which fuels its proprietary technologies and product differentiation. Its diagnostics segment, particularly in molecular testing, has shown strong growth, positioning Hologic well in the expanding global healthcare market. 2 Outstanding Stocks Under $50 to Buy and Hold Now Nvidia's Bringing Sovereign AI to Germany. Should You Buy NVDA Stock Here? A $1 Billion Reason to Buy MicroStrategy Stock Here Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. However, HOLX shares have retreated 24.5% from their 52-week high of $84.67 touched on Aug. 9, 2024. Meanwhile, HOLX stock has surged 3.2% over the past three months, surpassing the SPDR S&P Health Care Equipment ETF's (XHE) 4.8% plunge over the same time frame. HOLX stock has plummeted 11.3% on a YTD basis and 10.5% over the past 52 weeks, compared to XHE's 10.6% dip in 2025 and a 6.3% fall over the past year. The stock has remained consistently below its 200-day moving average since early December last year, but has climbed above its 50-day moving average since late May. On May 27, HOLX shares surged more than 14%, leading S&P 500 gainers, after reports emerged that TPG Inc. (TPG) and Blackstone Inc. (BX) made (and were turned down on) a non-binding ~$16 billion takeover bid, valuing the company at $70–$72 per share. The stock's rally reflected investor optimism and underscored the premium valuation placed on its leadership in women's health and diagnostic capabilities. In the competitive healthcare equipment industry, top rival, Align Technology, Inc.'s (ALGN) 13.7% drop on a YTD basis and 25.7% decline over the past year trails HOLX's losses in the same time frames. Among the 19 analysts covering the HOLX stock, the consensus rating is a 'Moderate Buy.' Its mean price target of $68.27 suggests a 6.7% upside potential from current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead?
Medical Properties Trust has a 7.2% yield and a history of dividend cuts behind it. Other healthcare REITs have high yields and dividends that have withstood adversity much better. Omega Healthcare has a 7.4% yield, and LTC Properties has a 6.5% yield. 10 stocks we like better than Medical Properties Trust › Medical Properties Trust (NYSE: MPW) has a lofty 7.2% yield. That compares to the S&P 500 index's skinny little 1.2% yield, and the average real estate investment trust's (REIT's) yield of around 4.1%. On the surface, it appears to be an obvious choice. But don't jump at the chance to buy Medical Properties Trust just yet. You can get similarly large yields from healthcare REIT peers Omega Healthcare (NYSE: OHI) and LTC Properties (NYSE: LTC), and both offer a more compelling dividend story than Medical Properties. Here's what you need to know. Take a look at the chart below for Medical Properties Trust. The orange line is the quarterly dividend, and the purple line is the stock price. Notice the massive drop in both that has occurred since 2022. That was when some of the REIT's large tenants started to experience financial troubles. It was the start of a tense and complicated period when a small number of Medical Properties Trust's tenants failed, and it had no choice but to cut its dividend. For long-term dividend investors, the lofty 7.2% yield on offer from Medical Properties Trust comes with some lofty risks. It's possible that the bad news is all out, and the REIT can start to turn its business around. However, that's far from a certainty. Unless you're willing to bet that the future will look much brighter from here, most dividend investors will probably want to tread with caution. In fact, even if a turnaround is underway, it's likely to be a years-long process. There's a contrast to be made here with healthcare REITs Omega Healthcare and LTC Properties. Both of these REITs focus on senior housing, including nursing homes and assisted living facilities. During the coronavirus pandemic's height, both of these property types were hard hit. The reason was pretty simple: COVID-19 is particularly deadly for unvaccinated older adults and spreads easily in group settings. Occupancy fell for both REITs, and there was a drought of new customers. Both Omega and LTC also had to deal with tenant problems, as some of their lessees had trouble paying rent. That would seem like a perfect storm that would lead to a dividend cut. Yet neither Omega nor LTC cut their dividends. To be fair, neither of these REITs has increased their dividends in years. But a static dividend is much better than a dividend cut. Right now, Omega's yield is 7.4%, while more diversified LTC Properties has a 6.5% yield. The future is starting to look brighter for each of these healthcare REITs. Omega's adjusted funds from operations (FFO) rose year over year in the first quarter of 2025, and it increased its full-year guidance. LTC Properties, meanwhile, expects 2025's adjusted FFO per share to be flat to slightly higher. However, it's diversifying its business approach to include senior housing operating properties (SHOP). (SHOP assets are owned and operated by the REIT, though it actually hires a third party to handle day-to-day management of the asset.) As it grows, this business should increasingly benefit from the growth in demand for senior housing as the U.S. population ages. The key takeaway here, however, is that, when faced with adversity, Omega and LTC Properties held firm in their commitment to shareholders. They adjusted as needed to keep paying. Medical Properties Trust, on the other hand, couldn't manage that feat. The past doesn't predict the future, of course, but the past is all we have to go on as investors. And since all three of these healthcare REITs have faced material adversity just recently, their strengths and weaknesses have been laid bare. While the worst might be over for Medical Properties Trust, most dividend investors should probably err on the side of caution with either Omega, which has a higher yield, or LTC Properties, which has a lower yield but a far more diversified business model. Before you buy stock in Medical Properties Trust, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medical Properties Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead? was originally published by The Motley Fool Sign in to access your portfolio
